Tauriga Sciences, Inc. Converts its U.S. Provisional Patent Application (Filed on March 17, 2020) to a U.S. Non-Provisional Patent Application
Tauriga Sciences, Inc. (TAUG) has recently filed an additional U.S. Provisional Patent Application for alternative pharmaceutical cannabinoid delivery systems. This complements the conversion of a prior U.S. Provisional Patent to a Non-Provisional Patent Application regarding its pharmaceutical cannabinoid chewing gum, aimed at treating nausea from chemotherapy. The company is making significant strides in its pharmaceutical development initiatives and anticipates updates on clinical trials soon. Tauriga also produces a variety of CBD and CBG infused chewing gums under the Tauri-Gum brand.
- Filed additional U.S. Provisional Patent Application to enhance IP portfolio.
- Converted a previous patent application to a Non-Provisional Patent Application.
- Continues to make significant progress in pharmaceutical development.
- Expecting to provide updates on clinical trials in the near term.
- None.
To Enhance Its Existing Intellectual Property Portfolio, the Company Filed an Additional U.S. Provisional Patent Application Directed to: Alternative Pharmaceutical Cannabinoid Delivery Systems
NEW YORK, NY, March 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that on March 17, 2021, the Company converted its U.S. Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application. This Non-Provisional Patent Application relates to the Company’s proposed Pharmaceutical Cannabinoid Chewing Gum Delivery System – being developed to treat: Nausea Derived from Active Chemotherapy Treatment.
Also on March 17, 2021, to enhance its existing intellectual property (“IP”) portfolio, the Company filed an additional U.S. Provisional Patent Application directed to: Alternative Pharmaceutical Cannabinoid Delivery Systems.
The Company continues to realize important and material progress with respect to its ongoing Pharmaceutical development efforts. The Company expects to provide additional update(s) to shareholders (relating to clinical trials), within the near term.
ABOUT TAURIGA SCIENCES, INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum™. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.
4 Nancy Court, Suite 4
Wappingers Falls, NY 12590
Chief Executive Officer
Mr. Seth M. Shaw
Email: sshaw@tauriga.com
Cell # (917) 796 9926
Company Instagram: @taurigum
Personal Instagram: @sethsms47
Twitter: @SethMShaw
Corp. Website: www.tauriga.com
E-Commerce Website: www.taurigum.com
FAQ
What is the latest patent application filed by Tauriga Sciences, Inc. (TAUG)?
What is the purpose of the Non-Provisional Patent Application filed by Tauriga (TAUG)?
When did Tauriga Sciences file its latest patent applications?
What are Tauriga's primary products?
What is Tauriga's focus in pharmaceutical development?
